Lancet neurology
-
Randomized Controlled Trial Multicenter Study
Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial.
The primary outcome results for the SPS3 trial suggested that a lower systolic target blood pressure (<130 mm Hg) might be beneficial for reducing the risk of recurrent stroke compared with a higher target (130-149 mm Hg), but that the addition of clopidogrel to aspirin was not beneficial compared with aspirin plus placebo. In this prespecified secondary outcome analysis of the SPS3 trial, we aimed to assess whether blood pressure reduction and dual antiplatelet treatment affect changes in cognitive function over time in patients with cerebral small vessel disease. ⋯ US National Institute of Neurological Disorders and Stroke.
-
Elizabeth Bradbury is a Medical Research Council Senior Fellow at King's College London (London, UK). She trained as a neuroscientist at the Institute of Psychiatry and St Thomas' Hospital in London before becoming a group leader at King's in 2003. Her research focuses on understanding processes of injury and repair and developing therapies to restore function following CNS trauma, with a particular interest in glial scarring, extracellular matrix modification, and neuroplasticity after spinal cord injury.